NCT04065399 2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT06284486 2026-02-25
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05731947 2026-01-29
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT07356154 2026-01-21
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting